Am J Cancer Res 2013;3(2):117-126
Review Article
Leptomeningeal metastases in breast cancer
Brian J Scott, Santosh Kesari
Department of Neurology, UC San Francisco, San Francisco, CA; Department of Neurosciences, Moores Cancer Center, UC San
Diego, La Jolla, CA; Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA, USA
Received January 15, 2013; Accepted March 2, 2013; Epub April 3, 2013; Published April 13, 2013
Abstract: Central nervous system (CNS) metastasis from breast cancer may be characterized as either parenchymal brain
metastasis (BM) or leptomeningeal (LM) metastasis. BM are much more common (about 80% of all CNS metastases), and have
been more extensively studied than LM. CNS metastasis in breast cancer has been associated with reduced overall survival,
with the shortest survival generally observed in cases of LM. Here, we review the epidemiology, prognostic factors, diagnostic
tools, currently available treatments, and potential future therapies for LM from breast cancer. (AJCR0000173)
Keywords: Leptomeningeal metastases, intrathecal chemotherapy, breast cancer
Address correspondence to: Dr. Santosh Kesari, Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA
92093, USA. Phone: 858-822-6346; Fax: 858-822-3033; E-mail: skesari@ucsd.edu
Review Article
Leptomeningeal metastases in breast cancer
Brian J Scott, Santosh Kesari
Department of Neurology, UC San Francisco, San Francisco, CA; Department of Neurosciences, Moores Cancer Center, UC San
Diego, La Jolla, CA; Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA, USA
Received January 15, 2013; Accepted March 2, 2013; Epub April 3, 2013; Published April 13, 2013
Abstract: Central nervous system (CNS) metastasis from breast cancer may be characterized as either parenchymal brain
metastasis (BM) or leptomeningeal (LM) metastasis. BM are much more common (about 80% of all CNS metastases), and have
been more extensively studied than LM. CNS metastasis in breast cancer has been associated with reduced overall survival,
with the shortest survival generally observed in cases of LM. Here, we review the epidemiology, prognostic factors, diagnostic
tools, currently available treatments, and potential future therapies for LM from breast cancer. (AJCR0000173)
Keywords: Leptomeningeal metastases, intrathecal chemotherapy, breast cancer
Address correspondence to: Dr. Santosh Kesari, Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA
92093, USA. Phone: 858-822-6346; Fax: 858-822-3033; E-mail: skesari@ucsd.edu
| AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 | |  | |  | |  | |  | |  | |  | |  |
American Journal of Cancer Research
| ISSN: 2156-6976 |